- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05590364
Aesthetic Performance and Tolerance of an Injective Intradermal Treatment for the Skin Roughness and Laxity of Back of the Hands
Interventional, Post-marketing, Local, Mono-centric Study for Evaluation of Aesthetic Performance and Tolerance of an Injective Intradermal Treatment for the Skin Roughness and Laxity of Back of the Hands
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Open, monocentric. 3 visits, 55 subjects.
Primary endpoint of the study is the evaluation of performance and tolerance of Profhilo Body (3ml) treatment in the back of the hands ( or dorsum of the hands). Secondary endpoint is self-assessment questionnaire by both doctors and volunteers.
Profhilo® Body (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 3.25 ml non-pyrogenic pre-filled syringe, containing 3 ml of 3.2% hyaluronic acid for intradermal use (48 mg H-HA + 48 mg L-HA) dissolved in 3 ml of saline buffered sodium chloride. - IBSA Farmaceutici Italia S.r.l. - ITALY. The principle component is cross-linked Hyaluronic Acid of non-animal origin, produced by bacterial fermentation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Adele Sparavigna, MD
- Phone Number: 02-23183475
- Email: adele.sparavigna@derming.com
Study Contact Backup
- Name: Roberto Lualdi, MD
- Phone Number: 02-23183475
- Email: adele.sparavigna@derming.com
Study Locations
-
-
Lombardia
-
Milano, Lombardia, Italy
- DERMING S.r.l., Clinical Research and Bioengineering Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria: Will be included in the study volunteers with the following characteristics:
- female and male sex, not necessarily 1:1 ratio;
- age 18-65 years;
- asking for hands restoration;
- available and able to return to the study site for the post-procedural follow-up examinations;
- accepting to not change their habits regarding food, physical activity, cosmetic and cleansing products for the hands;
- accepting not to expose their hands to strong UV irradiation (UV session, or sun bathes) during the entire duration of the study, without appropriate sun protection;
Exclusion Criteria:
- Pregnancy;
- lactation;
- smokers;
- alcohol or drug abusers;
- subjects not in menopause who do not use adequate contraceptive precautions in order to avoid pregnancies during the study;
- Body Mass Index (BMI) variation (± 1) during the study period;
- performing non-surgical skin aesthetic procedures for hands in the 6 months prior to the study start;
- aesthetic surgical procedure for the hands in the past;
- change in the normal habits regarding food, physical activity, cosmetic products and cleansing for the hands during the month preceding the test;
- sensitivity to the test product or its ingredients (to be assessed by the investigator during the baseline visit);
- subjects whose insufficient adhesion to the study protocol is foreseeable;
- participation in a similar study currently or during the previous 6 months.)
- presence of cutaneous disease on the tested area, as lesions, scars, malformations;
- clinical and significant skin condition on the test area (e.g. active eczema, psoriasis, sclerodermia, local infections).
Exclusion criteria due to systemic disease:
- Diabetes;
- endocrine disease;
- hepatic disorder;
- renal disorder;
- cardiac disorder;
- pulmonary disease;
- cancer;
- neurological or psychological disease;
- inflammatory/immunosuppressive disease;
- drug allergy Exclusion criteria due to ongoing pharmacological treatment
- Anticoagulants and antiplatelet drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago);
- using of drugs able to influence the test results in the investigator opinion. The use of other drugs, not mentioned above, can be authorized by the Investigator. The trade name, the dosage, the start and stop date of the therapy will be reported on concomitant medication form.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Profhilo® Body treatment group
1.5 ml per hand injected by a blunt tip microcannula (25G or 22G, preferably 22G), with fanning technique through a single entry point performing 5 passages and injecting 0,3 ml per passage. Day 0: Information and consent form provided. Clinical photography, Clinical assessment, Instrumental assessment, First treatment of Profhilo® (refer to study protocol). Day 30 (1 month after day 0): Clinical photography, Clinical assessment, Instrumental assessment, Second treatment of Profhilo® (refer to study protocol), Self-evaluation questionnaire. Day 120 (4 months after day 0): Clinical photography, Clinical assessment, Instrumental assessment, NO treatment, Self-evaluation questionnaire. |
Dosage form: Profhilo® Body (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 3.25 ml non-pyrogenic pre-filled syringe, containing 3 ml of 3.2% hyaluronic acid for intradermal use (48 mg H-HA + 48 mg L-HA) dissolved in 3 ml of saline buffered sodium chloride.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline of Skin Roughness and flaccidity at 30 days and at 120 days post-injection
Time Frame: Day 0, Day 30, Day 120
|
Visual score from 1 (no roughness and flaccidity) to 5 (very severe roughness and flaccidity)
|
Day 0, Day 30, Day 120
|
Change from Baseline of Skin density (profilometry) at 30 days and at 120 days post-injection
Time Frame: Day 0, Day 30, Day 120
|
A picture of the skin is taken thanks to Primos compact portable device (GFMesstechnik) and a 3D representation is elaborated by Primos software.
|
Day 0, Day 30, Day 120
|
Change from Baseline of Superficial and deep skin plastoelasticity at 30 days and at 120 days post-injection
Time Frame: Day 0, Day 30, Day 120
|
Measurement of the principal torsiometric parameters Ue (immediate extensibility), Uf (final extensibility), Uv (viscoelasticity) and Ur (immediate elastic recovery) by the instrument Dermal Torque Meter (Dia-Stron Ltd., UK)
|
Day 0, Day 30, Day 120
|
Change from Baseline of Tissue dielectric constant value of superficial and deep skin layers at 30 days and at 120 days post-injection
Time Frame: Day 0, Day 30, Day 120
|
Non-invasive measurements of dielectric constant of the skin and subcutaneous fat by MoistureMeterD (Delfin Technologies, Kuopio - Finland).
MoistureMeterD measures the changes in the total water content in the tissue with 0.5mm and 1.5mm probes.
|
Day 0, Day 30, Day 120
|
Change from Baseline of Photographic evaluation at 30 days and at 120 days post-injection
Time Frame: Day 0, Day 30, Day 120
|
2D pictures of the dorsum of both hands are taken in order to support the aesthetic result assessment
|
Day 0, Day 30, Day 120
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy questionnaire
Time Frame: Day 30, Day 120
|
Self-assessment questionnaire regarding skin roughness and laxity of the treated areas, skin suppleness, skin smoothness, skin hydration, skin lifting, contour redefinition/remodeling (score: very marked; marked; medium; light; absent)
|
Day 30, Day 120
|
Treatment tolerance questionnaire
Time Frame: Day 30, Day 120
|
Self-assessment score: bad; poor; good; excellent
|
Day 30, Day 120
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Adele Sparavigna, MD, DERMING S.r.l., Clinical Research and Bioengineering Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- E0122
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Laxity
-
Rocky Mountain Biosystems, Inc.CompletedLaxity of SkinUnited States
-
Rocky Mountain Biosystems, Inc.CompletedLaxity of SkinUnited States
-
Merz North America, Inc.Ulthera, IncCompletedMild to Moderate Skin Laxity Under the Chin | Mild to Moderate Skin Laxity on NeckUnited States
-
Apsara Medical CorporationCompleted
-
Ulthera, IncCompletedSkin Laxity of the décolletéUnited States
-
Ulthera, IncUniversity of Texas Southwestern Medical CenterCompletedMild to Moderate Skin Laxity on Cheek | Mild to Moderate Skin Laxity on Upper Neck | Mild to Moderate Subcutaneous Fat on Cheek | Mild to Moderate Subcutaneous Fat on Upper Neck
-
Derming SRLCompletedFace Skin LaxityItaly
-
Nashville Centre for Laser and Facial SurgeryBausch HealthUnknownFacial Skin Laxity
-
Ulthera, IncCompletedFacial Skin LaxityUnited States
-
Endo PharmaceuticalsCompletedLaxity; Skin | Cellulite | Edematous Fibrosclerotic PanniculopathyUnited States
Clinical Trials on Profhilo® Body
-
Derming SRLCompletedSkin ManifestationsItaly
-
Derming SRLCompletedSkin Flaccidity and Roughness of the Abdomen and Inner ArmsItaly
-
Derming SRLCompletedMalar and Sub-malar Volume DeficiencyItaly
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
University of ArizonaTerminated
-
Derming SRLCompletedSkin Flaccidity Inner Thighs Knees ArmsItaly
-
University of Santa Cruz do SulUnknownAging | Oxidative Stress
-
Sheba Medical CenterUnknownBrain Ischemia | Child | Congenital Heart Defects | Hypothermia, Induced | Hypoxia Brain
-
Universidad de ZaragozaUnknown
-
Bern University of Applied SciencesGoethe University; Maastricht University Medical Center; Swiss Federal Institute...CompletedDistorted; Balance